title: Recent developments in desensitization of crossmatch-positive kidney transplant recipients.
abstract: Currently, there are two major options for the successful and timely transplantation of sensitized kidney transplant recipients: (1) avoidance of the sensitization barrier using special allocation programs, or (2) desensitization. In the case of broadly sensitized kidney patients, a combination of both options might be necessary. This review focuses on new advances in desensitization of crossmatch-positive kidney transplant recipients which include immunoadsorption and the administration of new substances such as the complement C5 inhibitor eculizumab. Finally, integrated algorithms that combine different measures are acknowledged.
authors: Department of Nephrology, University of Heidelberg, Germany.
authors: C
authors: C
authors: Morath
authors: G
authors: G
authors: Opelz
authors: M
authors: M
authors: Zeier
authors: C
authors: C
authors: Süsal
mesh_terms: D000465:Algorithms; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003888:Desensitization, Immunologic / Q000639:trends*; D046148:Donor Selection; D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D006648:Histocompatibility; D006650:Histocompatibility Testing; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007518:Isoantibodies / Q000097:blood*; D016030:Kidney Transplantation / Q000276:immunology*; D010956:Plasmapheresis / Q000639:trends; D014019:Tissue Donors; D023001:Transplantation Tolerance; D016896:Treatment Outcome
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D006680:HLA Antigens; D016756:Immunoglobulins, Intravenous; D007518:Isoantibodies; C481642:eculizumab